Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors.
Chow E, Clement S, Garg R.
BMJ Open Diabetes Res Care. 2023 Oct;11(5):e003666. doi: 10.1136/bmjdrc-2023-003666.
Diabetic ketoacidosis.
Calimag APP, Chlebek S, Lerma EV, Chaiban JT.
Dis Mon. 2023 Mar;69(3):101418. doi: 10.1016/j.disamonth.2022.101418. Epub 2022 May 14.
Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State.
Fayfman M, Pasquel FJ, Umpierrez GE.
Med Clin North Am. 2017 May;101(3):587-606. doi: 10.1016/j.mcna.2016.12.011.
Diabetic ketoacidosis.
Dhatariya KK, Glaser NS, Codner E, Umpierrez GE.
Nat Rev Dis Primers. 2020 May 14;6(1):40. doi: 10.1038/s41572-020-0165-1.
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
Qiu H, Novikov A, Vallon V.
Diabetes Metab Res Rev. 2017 Jul;33(5). doi: 10.1002/dmrr.2886. Epub 2017 Feb 23.
Management of diabetic ketoacidosis.
Barski L, Golbets E, Jotkowitz A, Schwarzfuchs D.
Eur J Intern Med. 2023 Nov;117:38-44. doi: 10.1016/j.ejim.2023.07.005. Epub 2023 Jul 5.
The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management.
Nyenwe EA, Kitabchi AE.
Metabolism. 2016 Apr;65(4):507-21. doi: 10.1016/j.metabol.2015.12.007. Epub 2015 Dec 19.
Defining and characterising diabetic ketoacidosis in adults.
Dhatariya KK.
Diabetes Res Clin Pract. 2019 Sep;155:107797. doi: 10.1016/j.diabres.2019.107797. Epub 2019 Jul 22.
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB.
Diabetes Care. 2015 Sep;38(9):1687-93. doi: 10.2337/dc15-0843. Epub 2015 Jun 15.
SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
He Z, Lam K, Zhao W, Yang S, Li Y, Mo J, Gao S, Liang D, Qiu K, Huang M, Wu J.
Acta Diabetol. 2023 Mar;60(3):401-411. doi: 10.1007/s00592-022-02015-6. Epub 2022 Dec 28.
